Treatment with immunotherapy alone produces 'exceptional' response rates in some melanoma patients
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination ...
Apr 17, 2023
0
2